1.Low-density lipoprotein cholesterol target attainment in patients with stable or acute coronary heart disease in the Philippines: Results from the Dyslipidemia international study II
Rody G. Sy ; Maria Teresa B. Abola ; Baishali Ambegaonkar ; Roy Joseph M. Barcinas ; Philippe Brudi ; Martin Horack ; Dominik Lautsch ; Aurora G. Macaballug ; Eugenio B. Reyes ; Noel L. Rosas ; Domingo P. Solimen ; Ami Vyas ; Christy S. Yao ; Maria Delfa T. Zanoria ; Anselm K. Gitt
Acta Medica Philippina 2018;52(61):494-501
Objective:
To quantify the extent of hyperlipidemia and its treatment in patients with stable coronary heart disease (CHD) or an acute coronary syndrome (ACS) in the Philippines.
Methods:
The Dyslipidemia International Study (DYSIS) II was an observational, multinational study conducted in patients aged ≥18 years with stable CHD or being hospitalized with an ACS. A full lipid profile was evaluated at baseline, and for the ACS cohort, at 4 months after discharge from hospital. Achievement of low-density lipoprotein cholesterol (LDL-C) targets and the use of lipid-lowering therapy (LLT) were assessed.
Results:
A total of 232 patients were enrolled from 10 centers in the Philippines, 184 with stable CHD and 48 being hospitalized with an ACS. The mean LDL-C level for the CHD patients was 88.0±40.1 mg/dL, with 33.3% achieving the target of <70 mg/dL recommended for very high-risk patients. For the ACS cohort, the mean LDL-C level was 109.0±48.5 mg/dL, with target attainment of 25.0%. The majority of the CHD cohort was being treated with LLT (97.3%), while 55.3% of the ACS patients were receiving LLT prior to hospitalization, rising to 100.0% at follow-up. There was little use of non-statins.
Conclusions
For these very high-risk patients from the Philippines, LDL-C target attainment was poor. Opportunities for better monitoring and treatment of these subjects are being missed.
Cholesterol
;
Hydroxymethylglutaryl-CoA Reductase Inhibitors
;
Coronary Disease
;
Acute Coronary Syndrome
;
Myocardial Infarction